Equities research analysts at StockNews.com began coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) in a research report issued to clients and investors on Tuesday. The ...

DelveInsight's Peptide-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

Detailed price information for Preveceutical Medical Inc (PRVCF) from The Globe and Mail including charting and trades.

StockNews.com began coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Free Report) in a research report report ...

Holdingannounced that the U.S. Bankruptcy Court for the Southern District of Texas has extended the expiration of the ...

Dr. Jerome Zeldis and Dr. Blythe Sather bring exceptional backgrounds in cell therapy and solid tumorsCAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ERNA), a leader in cell therapies ...

He also brings experience as an executive or board member at NexImmune, Sorrento Therapeutics, Sandoz Research Institute, Janssen Research Institute, PTC Therapeutics, Soligenix, and NexGel.

CAMBRIDGE, Mass. - Eterna Therapeutics (NASDAQ:ERNA), a biotechnology company specializing in cell therapies for solid tumors, announced the appointment of two new members to its scientific ...

The upstart, clinical stage biotech company Viking Therapeutics, Inc. (NASDAQ:VKTX), which is attempting to disrupt their market leadership has also suffered from a protracted hangover ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.